Quicker and slicker: new initiatives to improve clinical trial delivery
November 16, 2011Research and Development
Faster study set-up times, reduced bureaucracy and timely patient recruitment – these things are central to the success of commercial …
Infectious diseases versus clinical researchers. Who is winning?
November 16, 2011Research and Development
They were running hand in hand, and the Queen went so fast that it was all she could do to …
Full service CROs: a cost-effective option for global therapeutically focused clinical development expertise
November 16, 2011Research and Development
Skyrocketing clinical development costs are bad news for everyone, from pharmaceutical companies to patients. That’s why it’s crucial we find …
Emerging markets: comparing India and China as the future R&D hubs for the pharmaceutical industry
November 16, 2011Research and Development
The pharmaceutical industry is expanding worldwide. For the last few years, the emerging markets that offer the dynamics of growth …
Boehringer invests $65 million in early R&D centre
November 16, 2011Research and Development, Sales and Marketing Boehringer Ingelheim
Boehringer Ingelheim is investing $65 million for an early-stage research and development centre in the US. The new 72,000 sq.ft. …
Pharmacovigilance in the EU – recent and future changes
November 15, 2011Research and Development
Changes to both post-marketing and clinical trial requirements
Boehringer developing Facebook game
November 15, 2011Medical Communications Boehringer Ingelheim, Facebook
Boehringer Ingelheim is developing a new Facebook civilisation game in the hopes of helping the public understand the difficulty involved …
The roles and responsibilities of an EEA qualified person for pharmacovigilance (QPPV)
November 15, 2011Research and Development
The roles and responsibilities of an EEA Qualified Person for Pharmacovigilance are based on the current Directive 2001/83/EC and Vol …
Merck’s vorapaxar fails in late-stage trial
November 15, 2011ACS, Brilinta, Efient, Merck, Plavix, antiplatelet, vorapaxar
Merck’s novel blood thinner vorapaxar has failed to meet its primary endpoint in a late-stage study.The TRACER trial compared vorapaxar …
UCB will double staff at Swiss bioproduction facility
November 15, 2011Manufacturing and Production UCB, manufacturing
Belgian pharmaceutical company UCB showcased its new bioproduction facility in Bulle, Switzerland, yesterday, saying that the workforce there looks set …
Joachim Christ to lead corporate controlling at Merck KGaA
November 15, 2011Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Merck KGaA
Joachim Christ will join Merck KGaA on 1 January next year as its new head of corporate controlling. Christ, 46, …
China’s SFDA starts overseas inspections
November 15, 2011Manufacturing and Production China, SFDA, manufacturing and production
China’s State Food and Drug Administration (SFDA) has started to inspect overseas manufacturing facilities in yet another sign of the …
Sanofi’s Lemtrada beats Rebif in new study
November 14, 2011Research and Development, Sales and Marketing Lemtrada, Rebif, Sanofi
Lemtrada has beaten Merck Serono’s multiple sclerosis treatment Rebif in a new head-to-head trial, paving the way for regulatory submission …
Mark Greener appointed editorial director at Rock Medical Communications
November 14, 2011Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Mark Greener, Rock Medical Communications
Rock medical communications has appointed journalist and medical writer Mark Greener as editorial director. Mark spent a decade in the …
The ABPI’s new leader: communicating pharma’s value
November 14, 2011Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, Stephen Whitehead
When Richard Barker, the ABPI’s director general decided to step down in May this year after six and a half …
BMS boosts access to HIV drug Reyataz in Brazil
November 14, 2011Manufacturing and Production, Sales and Marketing
Bristol-Myers Squibb has signed a technology transfer agreement with the Brazilian Ministry of Health to expand access to once-daily HIV …
Medical meetings and events – how to make the most of your budget
November 14, 2011Sales and Marketing
In today’s uncertain economic climate, much like every other form of marketing and business expenditure, event budgets are under scrutiny …
Eliquis fails in head-to-head study against Lovenox
November 14, 2011Research and Development, Sales and Marketing BMS, Eliquis, Lovenox, Pfizer
Bristol-Myers Squibb and Pfizer have suffered a setback in their attempts to cement Eliquis’ place in the $20 billion market …
CMO WellSpring brought by private equity firms
November 14, 2011Manufacturing and Production
WellSpring Pharmaceutical Corp has been acquired by private equity group Ancor Capital Partners in a deal which looks set to …
Genzyme appoints new leaders for multiple sclerosis and rare disease businesses
November 14, 2011Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Genzyme
Genzyme, a Sanofi company, has appointed William Sibold as head of multiple sclerosis and Rogério Vivaldi as head of rare …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
